Outlook Therapeutics Fails Nasdaq Continued Listing Standard
Outlook Therapeutics received a Nasdaq notice on September 25, 2026, stating its common stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has until March 24, 2027, to regain compliance.